About Us
BELLUS Health is a clinical stage biotechnology company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of refractory chronic cough. The Company has initiated the CALM Phase 3 program, which consists of two pivotal trials CALM-1 and CALM-2. BELLUS Health is also exploring how inhibition of P2X3 receptors can help treat other afferent hypersensitization-related disorders.
We invite you to visit our investors’ relations page, including our Annual Information Form, to obtain more information about BELLUS Health.